OKUROnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. (OKUR) is a biopharmaceutical company focused on the development of novel therapies for rare and orphan diseases. The next catalyst is Oct 15, 2026 — Pipeline Prioritization & Capital Allocation Review, which will test the company’s ability to allocate resources effectively and prioritize its most promising assets.
- OKUR has a $192M cash balance, providing a runway for clinical development and strategic flexibility.
- The company has no revenue and is heavily reliant on equity financing and grants.
- Its financials are characterized by negative net income and free cash flow, with a focus on long-term therapeutic value over short-term profitability.
The Read
20 due to its $192M cash balance, then rallied further 50.
The schedule
- Thu15Oct
The review tests whether the company can reallocate capital to high-potential assets and maintain cash flow, unlike the last review which failed to address dilution risks.
- Tue10Nov
The earnings release will test the company's ability to meet guidance and provide clarity on cash burn and clinical progress, differing from the last print which missed revenue expectations.
- Tue1Dec
The data will test the company's ability to demonstrate dose efficacy and safety, unlike the last data release which showed mixed results and led to a sell-off.
- Fri18Dec
The feedback will test the company's ability to secure regulatory approval for Phase 2, differing from the last meeting which delayed the timeline and caused a drop.
- Sat13Feb
The outlook will test the company's ability to outline a clear development roadmap and cash flow plan, differing from the last print which lacked strategic clarity.
- Tue4May
The earnings release will test the company's ability to meet guidance and provide clarity on cash burn and clinical progress, differing from the last print which missed revenue expectations.
- Tue10Aug
- Tue14Sep
The conference participation will test the company's ability to generate investor interest and secure follow-on capital, differing from the last event which failed to attract significant attention.
Past
- Thu27Aug
Actual outcome: Bear · $2.34 at outcome
OKUR reported earnings below expectations and issued weaker-than-anticipated guidance, signaling challenges in near-term growth. The move reflects investor concerns over revenue shortfall and margin pressure, which triggered a sharp sell-off in the medium-term window. [Market retrospective · Medium-Term (11–30 days)] Missed anticipation: -37.2% from 2026-08-27 to 2026-10-09 (~2.3σ vs typical 30d vol). Target date 2026-09-17 reached; move through 2026-10-09 observed. Confidence 95%. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-10-12: -37.2% from 2026-08-27 (~2.3σ). Target date 2026-09-17 reached; move through 2026-10-12 observed. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-10-13: -36.0% from 2026-08-28 (~2.3σ). Target date 2026-09-17 reached; move through 2026-10-13 observed.
OKUR reported earnings below expectations and issued weaker-than-anticipated guidance, signaling challenges in near-term growth. The move reflects investor concerns over revenue shortfall and margin pressure, which triggered a sharp sell-off in the medium-term window. [Market retrospective · Medium-Term (11–30 days)] Missed anticipation: -37.2% from 2026-08-27 to 2026-10-09 (~2.3σ vs typical 30d vol). Target date 2026-09-17 reached; move through 2026-10-09 observed. Confidence 95%. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-10-12: -37.2% from 2026-08-27 (~2.3σ). Target date 2026-09-17 reached; move through 2026-10-12 observed. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-10-13: -36.0% from 2026-08-28 (~2.3σ). Target date 2026-09-17 reached; move through 2026-10-13 observed.
- Tue11Aug
Actual outcome: Bull · $4.21 at outcome
OnKure Therapeutics reported in-line EPS of -1.11, matching expectations, with no significant guidance changes. The stock rallied due to positive sentiment around the recent $150M private placement and stabilized cash runway, reinforcing investor confidence. The price exceeded the bull target, reflecting market optimism around the company's financial position and strategic direction.
Q2 earnings print focusing on the cash burn rate following the recent $150M private placement and adjusted operating expenses.
- Tue5May
Actual outcome: Bull · $4.20 at outcome
OKUR reported EPS of -1.11, matching expectations, and provided updated cash runway guidance, highlighting its $192M cash balance as a key support. The stock reached the bull target of $4.20, driven by the positive cash position and strategic clarity, despite a short-term pullback. The price action aligned with the bull case, reinforcing near-term fundamental support.
Q1 earnings will focus on OKUR's massive $192M cash balance versus its depressed market capitalization, establishing near-term fundamental support.